Compare SUVEN LIFE with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES CIPLA SUVEN LIFESCIENCES/
CIPLA
 
P/E (TTM) x 20.5 21.9 93.6% View Chart
P/BV x 4.1 2.4 172.8% View Chart
Dividend Yield % 0.5 0.7 75.8%  

Financials

 SUVEN LIFESCIENCES   CIPLA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
CIPLA
Mar-19
SUVEN LIFESCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs338678 49.8%   
Low Rs169484 35.0%   
Sales per share (Unadj.) Rs52.1198.2 26.3%  
Earnings per share (Unadj.) Rs6.818.5 36.9%  
Cash flow per share (Unadj.) Rs8.635.0 24.5%  
Dividends per share (Unadj.) Rs1.503.00 50.0%  
Dividend yield (eoy) %0.60.5 114.6%  
Book value per share (Unadj.) Rs65.3186.3 35.0%  
Shares outstanding (eoy) m127.28805.70 15.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.92.9 166.0%   
Avg P/E ratio x37.131.4 118.4%  
P/CF ratio (eoy) x29.616.6 178.2%  
Price / Book Value ratio x3.93.1 124.6%  
Dividend payout %22.016.2 135.6%   
Avg Mkt Cap Rs m32,272468,031 6.9%   
No. of employees `0001.122.6 4.8%   
Total wages/salary Rs m66128,565 2.3%   
Avg. sales/employee Rs Th6,132.27,053.1 86.9%   
Avg. wages/employee Rs Th611.11,261.5 48.4%   
Avg. net profit/employee Rs Th803.5659.1 121.9%   
INCOME DATA
Net Sales Rs m6,635159,710 4.2%  
Other income Rs m2424,766 5.1%   
Total revenues Rs m6,877164,475 4.2%   
Gross profit Rs m1,60430,973 5.2%  
Depreciation Rs m22113,263 1.7%   
Interest Rs m381,684 2.2%   
Profit before tax Rs m1,58720,791 7.6%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7185,695 12.6%   
Profit after tax Rs m86914,924 5.8%  
Gross profit margin %24.219.4 124.7%  
Effective tax rate %45.227.4 165.1%   
Net profit margin %13.19.3 140.2%  
BALANCE SHEET DATA
Current assets Rs m6,232124,266 5.0%   
Current liabilities Rs m1,49037,715 4.0%   
Net working cap to sales %71.554.2 131.9%  
Current ratio x4.23.3 126.9%  
Inventory Days Days8691 95.4%  
Debtors Days Days8395 87.1%  
Net fixed assets Rs m4,043105,190 3.8%   
Share capital Rs m1271,611 7.9%   
"Free" reserves Rs m8,183148,511 5.5%   
Net worth Rs m8,310150,123 5.5%   
Long term debt Rs m1838,301 0.0%   
Total assets Rs m10,389239,633 4.3%  
Interest coverage x43.113.3 323.0%   
Debt to equity ratio x00.3 0.8%  
Sales to assets ratio x0.60.7 95.8%   
Return on assets %8.76.9 126.0%  
Return on equity %10.59.9 105.2%  
Return on capital %19.511.8 164.9%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62257,410 9.8%   
Fx outflow Rs m1,79919,041 9.5%   
Net fx Rs m3,82238,368 10.0%   
CASH FLOW
From Operations Rs m35616,911 2.1%  
From Investments Rs m-279-16,687 1.7%  
From Financial Activity Rs m-225-3,487 6.5%  
Net Cashflow Rs m-148-3,451 4.3%  

Share Holding

Indian Promoters % 63.4 16.0 396.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 36.5 26.2 139.3%  
Shareholders   37,287 161,166 23.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling Pressure, Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

Indian share markets closed on a negative note yesterday amid weak global cues and disappointing domestic factory output data.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS